Business

TAAT® is preparing to take advantage of the recently announced plans for the new US Nicotine Regulations, the Canadian Business Journal.

Las Vegas and Vancouver, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) — TAAT® GLOBAL ALTERNATIVE SINC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (“Company” or “TAAT®”) Announces that it is taking proactive steps to take advantage of the plans proposed by the US Food and Drug Administration (“FDA”). This establishes the highest levels of nicotine in cigarettes and other combustible tobacco products (FDA June 21, 2022).1). In the FDA’s announcement, the FDA explained the role of nicotine as an attribute of tobacco products that contributes to the addiction of tobacco products and that it is “the main driving force for the sustainable use of these products”. did. [cigarettes]2“. In the fourth quarter of 2020, TAAT® launched nicotine-free and tobacco-free alternative tobacco in Ohio, based on the product’s innovative value proposition as an option for adult smokers to refrain from nicotine while having virtually continued enjoyment. It has expanded its position in the market rapidly. Similar “rituals” of lighting and smoking of flammable products. At the time of this writing, TAAT® is sold under the national banner in over 2,700 US retail stores, including independent shops and chain stores.

A further analysis of this announcement is covered in yesterday’s edition of the article. The Wall Street Journal: https://www.wsj.com/articles/biden-administration-targets-removal-of-most-nicotine-from-cigarettes-11655842130

The expected result from the proposed rule announced by the FDA is that tobacco tobacco in the United States contains lower levels of nicotine. This is undoubtedly due to the need to change the product prescription for the US version of the Legacy tobacco product (for example, Marlboro, Newport, Camel), If new formulations do not match the established taste due to low nicotine levels, US adult smokers may seek alternatives to their favorite brands. TAAT® Beyond Tobacco ™ base material is widely regarded by adult smokers as superior to real cigarettes with a “standard” nicotine content. Based on this similarity, despite not containing nicotine, we will propose TAAT in light of the FDA’s recently announced rules aimed at “restricting” nicotine levels in tobacco sold. We expect ® to prove to be even more attractive to adult smokers in the United States. In the United States.

A US patent is currently pending for the nicotine-free and tobacco-free Beyond Tobacco ™ formulations used in the manufacture of TAAT® products.

In an announcement dated June 21, 2022, the US Food and Drug Administration announced plans for a draft rule to establish the highest levels of nicotine in tobacco tobacco sold in the United States. We anticipate that such rules could prove to be advantageous for the company's flagship product, TAAT®, which is a nicotine and tobacco-free alternative to tobacco.

In an announcement dated June 21, 2022, the US Food and Drug Administration announced plans for a draft rule to establish the highest levels of nicotine in tobacco tobacco sold in the United States. We anticipate that such rules could prove to be advantageous for the company’s flagship product, TAAT®, which is a nicotine and tobacco-free alternative to tobacco.

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ed941322-4d5e-4331-bf42-5e529850d4e7.

Readers using news aggregation services may not be able to view the above media. SEDAR or Investor public relations See the section on our website for a version of this press release, including all published media.

Joe Deighan, founder of TAAT®, commented: It is clear that the FDA is aware of this, based on a plan that proposes rules to limit the amount of nicotine allowed in tobacco sold in the United States. We expect this to bring about significant changes in the US tobacco category. It can take advantage of the established offering of nicotine-free alternatives that feel much like regular cigarettes with standard levels of nicotine. We will continue to commercialize TAAT®, build on the existing footprint of our 2,700 US stores, and take proactive steps to take advantage of these new rules when they come into force. increase. “

sauce

1 – https://www.nytimes.com/2022/06/21/health/fda-nicotine-cigarettes.html

2 – https://www.fda.gov/news-events/press-announcements/fda-announces-plans-proposed-rule-reduce-addictiveness-cigarettes-and-other-combusted-tobacco

On behalf of our board of directors

TAAT® GLOBAL ALTERNATIVE SINC.

“Joe Dian”

Joe Dian, COO and Director

For more information, please contact:

TAAT® Investor Relations
1-833-TAAT-USA (1-833-822-8872)
[email protected]

The Canadian Stock Exchange (“CSE”) has not considered the accuracy or validity of this release and is not responsible for it. Also, there are no CSE regulatory service providers.

About TAAT® Global Alternatives Inc.

TAAT® develops, manufactures and distributes alternative products in categories including tobacco, hemp, kratom, and other emerging segments of the CPG industry. Its flagship product is a nicotine-free, tobacco-free cigarette with a patent-pending base material, sold in more than 2,700 US stores. With total net sales of more than $ 80 million in 2021, TAAT® facilities include a manufacturing plant in Nevada, a distribution center in Ohio, and multiple convenience stores.

For more information, please visit: http://taatglobal.com..

Description of future prospects

This news release contains “forward-looking information” in the sense of applicable Canadian securities law. In many cases, but not always, information or information about the future outlook is “planning,” “expecting,” “not expecting,” “expected,” “estimating,” “intended,” or “predicting.” “Do”, “Unpredict”, “Believe”, or variations of such words or phrases, or certain actions, events, or outcomes are “possible”, “possible”, “possible” Taken, occurred, or achieved, stating “yes”, “possible”, “possible”. Information about the future outlook for this news release includes a statement about the expected performance of TAAT® in the tobacco industry, in addition to: Possibility of establishing regulations on maximum nicotine levels in US cigarettes and expected performance of TAAT® under such circumstances. The forward-looking information reflects the current expectations of management based on the currently available information, with many risks that may result in significantly different results from those described in the forward-looking information. Affected by uncertainty. We believe that the assumptions and factors used to create forward-looking information are reasonable, but we should not place excessive reliance on such information and such events have been disclosed. There is no guarantee that it will not occur within the time frame or at all. Factors that may cause actual results or events to differ materially from current expectations include: (Ii) Growth and size changes in the tobacco market. (Iii) Changes in the regulatory environment that apply to our business. (Iv) Other factors beyond our control. We operate in a rapidly evolving environment. New risk factors occur from time to time and it is not possible for our management to predict all risk factors, and we have the impact of all factors on our business or any combination of factors or factors. It is also not possible to assess how much it affects. Actual results may differ from those contained in the forward-looking information. The forward-looking information contained in this news release was produced as of the date of this news release, and we will update or revise the forward-looking information as a result of new information, future events, etc. Explicitly deny an intention or obligation. , Except as required by applicable law.

The statement in this news release has not been evaluated by Health Canada or the US Food and Drug Administration. Due to individual differences, the benefits of taking our products vary from person to person. We cannot make any claims or warranties about the impact of our products on the health and well-being of individuals. Our products are not intended to diagnose, treat, cure or prevent any disease.

This news release typically has the trademark name (or brand name) of the third party entity with reference to (i) the company’s relationship with the third party entity mentioned in this release and / or (ii). Each product) may be included. ) In this release, client / vendor / service provider stakeholders whose relationships with the company are referenced. All rights to such trademarks are reserved by their respective owners or licensees.

Statement on a third-party investor public relations company

Disclosures regarding investor public relations firms owned by TAAT® Global Alternatives Inc. are under our profile. http://sedar.com..


CBJ News Maker

TAAT® is preparing to take advantage of the recently announced plans for the new US Nicotine Regulations, the Canadian Business Journal.

Source link TAAT® is preparing to take advantage of the recently announced plans for the new US Nicotine Regulations, the Canadian Business Journal.

Related Articles

Back to top button